Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Clinical trial failures of two drugs for hearing loss and tinnitus underscore pitfalls for a nascent area of drug development, but lessons learned may help in navigating the uncharted path to approval.
Nonalcoholic steatohepatitis (NASH), an extreme form of nonalcholic fatty liver disease, is predicted to become the leading reason for liver transplantation by 2020. This analysis provides an overview of emerging therapies for NASH.
Deborah Zarin, director ofClinicalTrials.gov, discusses the new trial registration rules and the need for transparency in the clinical research enterprise.
Although Agios and Celgene are set to file for approval for their first-in-class cancer metabolism drug, the field has started looking in new directions for the next batch of metabolic targets.
The growth of precision medicine presents challenges for the regulators of medicines, related to aspects that include the basis of evidence generation, patient involvement in the regulatory process, cost of new medicines and the need for new regulatory models. It also raises questions about the tolerance of risk, especially with early interventions for life-threatening diseases.